Andrew Purchase | Associate Director, Safety and Risk Management - Global Patient Safety

Andrew Purchase, Associate Director, Safety and Risk Management - Global Patient Safety, PRA

Andrew holds a Bachelor’s of Science (Hons) in Forensic Science from the University of Glamorgan, United Kingdom. Andrew has over 5 years’ experience in Pharmacovigilance in addition to 3 and a half years’ experience in Data Management. Andrew initially joined PRA Health Sciences in May 2006 as a Clinical Data Coordinator. During his three and a half years in Data Management Andrew was responsible for leading a number of projects over a range of therapeutic areas. In February 2010 Andrew moved into the drug safety team. In this role Andrew was again responsible for leading a number of projects as well as contributing significantly to the growth and success of the drug safety center. In December 2011 Andrew left PRA and joined GlaxoSmithKline as a Clinical Safety Scientist. During which time he gained advanced experience in post-marketing Pharmacovigilance activities including literature surveillance, collaboration with licensing partners and ensuring compliance with safety data exchange agreements. 

In July 2014 Andrew re-joined PRA Health Sciences as Safety Scientist. Since returning to PRA Health Sciences Andrew has been heavily involved in developing adjudication services, moving into a role of subject matter expert, as well as aggregate safety reporting (e.g. DSURs) and Pharmacovigilance System Master File (PSMF) generation. As Senior Safety Scientist, Andrew is also tasked with the development of literature services and forms a part of the Pharmacogenomics working group for PRA.  


Drug Safety World Day 1 @ 16:10

The adoption of Pharmacogenomics leading to patient benefit

  • Overviewing the increasing acceptance and adoption of Pharmacogenomics internationally
  • Translating the power of Pharmacogenomics into direct benefits for the patient to reduce ADEs
  • Methodologies for raising patient awareness and understanding of the potential benefits linked to Pharmacogenomics

back to speakers